Cargando…

Complement Inhibition in ANCA-Associated Vasculitis

Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tesar, Vladimir, Hruskova, Zdenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307875/ https://www.ncbi.nlm.nih.gov/pubmed/35880179 http://dx.doi.org/10.3389/fimmu.2022.888816

Ejemplares similares

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study
por: Frausová, Doubravka, et al.
Publicado: (2016)

Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA – associated vasculitis
por: Satrapova, Veronika, et al.
Publicado: (2023)

The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs
por: Kimoto, Yasutaka, et al.
Publicado: (2022)

Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis
por: Frydlova, Jana, et al.
Publicado: (2022)

Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy
por: Tesar, Vladimir, et al.
Publicado: (2021)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Animal Models of ANCA Associated Vasculitis
por: Shochet, Lani, et al.
Publicado: (2020)

The involvement of NETs in ANCA-associated vasculitis
por: Shiratori-Aso, Satoka, et al.
Publicado: (2023)

Neutrophil Extracellular Traps in ANCA-Associated Vasculitis
por: Söderberg, Daniel, et al.
Publicado: (2016)

Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis
por: Hladinova, Z., et al.
Publicado: (2015)

ANCA Vasculitis Induction Management During the COVID-19 Pandemic
por: Salas, Antonio, et al.
Publicado: (2021)

Environmental factors influencing the risk of ANCA-associated vasculitis
por: Zhao, Wen-Man, et al.
Publicado: (2022)

Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art
por: Bonatti, Francesco, et al.
Publicado: (2014)

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
por: Hartinger, Jan Miroslav, et al.
Publicado: (2022)

New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis
por: Nozaki, Yuji
Publicado: (2021)

Unmet needs in ANCA-associated vasculitis: Physicians’ and patients’ perspectives
por: Quartuccio, Luca, et al.
Publicado: (2023)

Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis
por: Sparding, Nadja, et al.
Publicado: (2021)

The Pathogenicity of BPI-ANCA in a Patient With Systemic Vasculitis
por: Takeda, Sayo, et al.
Publicado: (2019)

Implication of platelets and complement C3 as link between innate immunity and tubulointerstitial injury in renal vasculitis with MPO-ANCA seropositivity
por: Baier, Eva, et al.
Publicado: (2022)

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Geetha, Duvuru, et al.
Publicado: (2018)

Specific IgG glycosylation differences precede relapse in PR3-ANCA associated vasculitis patients with and without ANCA rise
por: Wojcik, Iwona, et al.
Publicado: (2023)

Extracellular neutrophil traps: a novel therapeutic target in ANCA-associated vasculitis?
por: Diamantopoulos, Andreas P.
Publicado: (2013)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Dysregulated Responsiveness of Circulating Dendritic Cells to Toll-Like Receptors in ANCA-Associated Vasculitis
por: Braudeau, Cécile, et al.
Publicado: (2017)

The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells
por: Werner, Kai, et al.
Publicado: (2019)

Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?
por: O'Sullivan, Kim M., et al.
Publicado: (2021)

Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis
por: Chen, Su-Fang, et al.
Publicado: (2015)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Erratum to: Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis
por: Chen, Su-Fang, et al.
Publicado: (2017)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Adult-Onset ANCA-Associated Vasculitis in SAVI: Extension of the Phenotypic Spectrum, Case Report and Review of the Literature
por: Staels, Frederik, et al.
Publicado: (2020)

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis
por: Thompson, Gwen E., et al.
Publicado: (2020)

Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies
por: Ui Mhaonaigh, Aisling, et al.
Publicado: (2019)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9h74mdmd3v9ipkc121kmfdi0v8